Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ECOSPOR IV: An Open-Label Extension of Study SERES-012 and Open-Label Program for Evaluating SER-109 in Subjects With Recurrent Clostridioides Difficile Infection (RCDI)

NCT03183141 is registered in ClinicalTrials.gov with Seres Therapeutics, Inc. as lead sponsor.

NCT NCT03183141
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03183141 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ECOSPOR IV: An Open-Label Extension of Study SERES-012 and Open-Label Program for Evaluating SER-109 in Subjects With Recurrent Clostridioides Difficile Infection (RCDI)
Lead sponsor
Seres Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
October 23, 2017
Completion date
April 29, 2022
Enrollment
263 (actual)
Sites
107

Conditions

As the registry lists them; a condition with its own page is linked.

clostridioides difficile infection